CDKN2A and malignant colon neoplasm: Therefore, we postulate that shikonin, through its ability to induce senescence in colon cancer cells, may effectively downregulate the expression of CXCL8 and CDKN2A. This process could potentially contribute to the inhibition of colon cancer development, offering a novel therapeutic approach.